Literature DB >> 32817337

Generation and validation of recombinant antibodies to study human aminoacyl-tRNA synthetases.

Charlotta Preger1, Edvard Wigren1, Elena Ossipova1, Carolyn Marks1, Johan Lengqvist2, Camilla Hofström3,4, Oskar Andersson3,4, Per-Johan Jakobsson1, Susanne Gräslund5, Helena Persson6,4.   

Abstract

Aminoacyl-tRNA synthetases (aaRSs) have long been viewed as mere housekeeping proteins and have therefore often been overlooked in drug discovery. However, recent findings have revealed that many aaRSs have noncanonical functions, and several of the aaRSs have been linked to autoimmune diseases, cancer, and neurological disorders. Deciphering these roles has been challenging because of a lack of tools to enable their study. To help solve this problem, we have generated recombinant high-affinity antibodies for a collection of thirteen cytoplasmic and one mitochondrial aaRSs. Selected domains of these proteins were produced recombinantly in Escherichia coli and used as antigens in phage display selections using a synthetic human single-chain fragment variable library. All targets yielded large sets of antibody candidates that were validated through a panel of binding assays against the purified antigen. Furthermore, the top-performing binders were tested in immunoprecipitation followed by MS for their ability to capture the endogenous protein from mammalian cell lysates. For antibodies targeting individual members of the multi-tRNA synthetase complex, we were able to detect all members of the complex, co-immunoprecipitating with the target, in several cell types. The functionality of a subset of binders for each target was also confirmed using immunofluorescence. The sequences of these proteins have been deposited in publicly available databases and repositories. We anticipate that this open source resource, in the form of high-quality recombinant proteins and antibodies, will accelerate and empower future research of the role of aaRSs in health and disease.
© 2020 Preger et al.

Entities:  

Keywords:  aminoacyl-tRNA synthetase; anti-synthetase syndrome; antibody validation; antigen; autoimmune disease; myositis; phage display; recombinant antibodies; recombinant protein expression; scFv

Year:  2020        PMID: 32817337      PMCID: PMC7549041          DOI: 10.1074/jbc.RA120.012893

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Myositis an evolving spectrum of disease.

Authors:  Simone Barsotti; Ingrid E Lundberg
Journal:  Immunol Med       Date:  2018-09-11

Review 2.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

3.  Reproducibility: Standardize antibodies used in research.

Authors:  Andrew Bradbury; Andreas Plückthun
Journal:  Nature       Date:  2015-02-05       Impact factor: 49.962

Review 4.  Recent Advances in Mitochondrial Aminoacyl-tRNA Synthetases and Disease.

Authors:  Marie Sissler; Ligia Elena González-Serrano; Eric Westhof
Journal:  Trends Mol Med       Date:  2017-07-14       Impact factor: 11.951

5.  In Vivo Biotinylation of Antigens in E. coli.

Authors:  Susanne Gräslund; Pavel Savitsky; Susanne Müller-Knapp
Journal:  Methods Mol Biol       Date:  2017

Review 6.  Essential nontranslational functions of tRNA synthetases.

Authors:  Min Guo; Paul Schimmel
Journal:  Nat Chem Biol       Date:  2013-03       Impact factor: 15.040

7.  Aminoacyl-tRNA synthetases and tRNAs in human disease: an introduction to the JBC Reviews thematic series.

Authors:  Karin Musier-Forsyth
Journal:  J Biol Chem       Date:  2019-02-24       Impact factor: 5.157

8.  Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis.

Authors:  Jie J Zhou; Feng Wang; Zhiwen Xu; Wing-Sze Lo; Ching-Fun Lau; Kyle P Chiang; Leslie A Nangle; Melissa A Ashlock; John D Mendlein; Xiang-Lei Yang; Mingjie Zhang; Paul Schimmel
Journal:  J Biol Chem       Date:  2014-06-04       Impact factor: 5.157

9.  Serum-circulating His-tRNA synthetase inhibits organ-targeted immune responses.

Authors:  Ryan A Adams; Cátia Fernandes-Cerqueira; Antonella Notarnicola; Elisabeth Mertsching; Zhiwen Xu; Wing-Sze Lo; Kathleen Ogilvie; Kyle P Chiang; Jeanette Ampudia; Sanna Rosengren; Andrea Cubitt; David J King; John D Mendlein; Xiang-Lei Yang; Leslie A Nangle; Ingrid E Lundberg; Per-Johan Jakobsson; Paul Schimmel
Journal:  Cell Mol Immunol       Date:  2019-12-04       Impact factor: 11.530

Review 10.  Autoantibodies in polymyositis and dermatomyositis.

Authors:  Anna Ghirardello; Nicola Bassi; Lavinia Palma; Elisabetta Borella; Marta Domeneghetti; Leonardo Punzi; Andrea Doria
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.686

View more
  3 in total

1.  Spike-Dependent Opsonization Indicates Both Dose-Dependent Inhibition of Phagocytosis and That Non-Neutralizing Antibodies Can Confer Protection to SARS-CoV-2.

Authors:  Wael Bahnan; Sebastian Wrighton; Martin Sundwall; Anna Bläckberg; Olivia Larsson; Urban Höglund; Hamed Khakzad; Magdalena Godzwon; Maria Walle; Elisabeth Elder; Anna Söderlund Strand; Lotta Happonen; Oscar André; Johannes Kumra Ahnlide; Thomas Hellmark; Vidar Wendel-Hansen; Robert Pa Wallin; Johan Malmstöm; Lars Malmström; Mats Ohlin; Magnus Rasmussen; Pontus Nordenfelt
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

2.  BRCA1 Antibodies Matter.

Authors:  Jing Yang; Leilei Qi; Huai-Chin Chiang; Bin Yuan; Rong Li; Yanfen Hu
Journal:  Int J Biol Sci       Date:  2021-07-25       Impact factor: 6.580

3.  Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain.

Authors:  Aleksandra Szykowska; Yu Chen; Thomas B Smith; Charlotta Preger; Jingjing Yang; Dongming Qian; Shubhashish M Mukhopadhyay; Edvard Wigren; Stephen J Neame; Susanne Gräslund; Helena Persson; Peter J Atkinson; Elena Di Daniel; Emma Mead; John Wang; John B Davis; Nicola A Burgess-Brown; Alex N Bullock
Journal:  Structure       Date:  2021-07-06       Impact factor: 5.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.